Literature DB >> 26707028

The importance of surgical margins in retroperitoneal sarcoma.

Amanda Kirane1,2, Aimee M Crago1,2.   

Abstract

Surgery is the "gold-standard" treatment for retroperitoneal sarcomas, but local recurrence is common, and can cause disease-related death. Complete gross resection is associated with improved survival, but debate exists as to whether resection of adjacent organs to improve margins or prescription of neoadjuvant radiation leads to better outcomes. This review summarizes data addressing prognostic value of margin, extent of surgery necessary to optimize treatment of retroperitoneal sarcomas, and role of histology in optimizing therapy.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  extended compartment resection; leiomyosarcoma; liposarcoma; retroperitoneal sarcoma

Mesh:

Year:  2015        PMID: 26707028     DOI: 10.1002/jso.24135

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

1.  Huge retroperitoneal liposarcoma with renal involvement requires nephrectomy: A case report and literature review.

Authors:  Jun Yang; Yue Zhao; Chun Hua Zheng; Qian Wang; Xue Yu Pang; Tian Wang; Jiao Jiao Ma
Journal:  Mol Clin Oncol       Date:  2016-09-14

Review 2.  Tumor Biological Aspects of Epithelial versus Mesenchymal Tumors of the Gastrointestinal Tract.

Authors:  Chandrajit P Raut
Journal:  Visc Med       Date:  2018-10-28

3.  Recurrence patterns after resection of retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative.

Authors:  Konstantinos Chouliaras; Rebecca Senehi; Cecilia G Ethun; George Poultsides; Thuy Tran; Valerie Grignol; Thomas Clark Gamblin; Kevin K Roggin; Jennifer Tseng; Ryan C Fields; Sharon M Weber; Gregory B Russell; Edward A Levine; Kenneth Cardona; Konstantinos Votanopoulos
Journal:  J Surg Oncol       Date:  2019-06-27       Impact factor: 3.454

4.  Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma.

Authors:  Derek J Erstad; Yi-Ju Chiang; Russell G Witt; Brandon Cope; Elise F Nassif; Christopher P Scally; Keila E Torres; Barry W Feig; Kelly K Hunt; Andrew J Bishop; B Ashleigh Guadagnolo; Christina L Roland; Emily Z Keung
Journal:  Ann Surg Oncol       Date:  2022-09-17       Impact factor: 4.339

Review 5.  Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review.

Authors:  Brian P Curry; Reinier Alvarez; Brigitte C Widemann; Matthew Johnson; Piyush K Agarwal; Tanya Lehky; Vladimir Valera; Prashant Chittiboina
Journal:  Oper Neurosurg (Hagerstown)       Date:  2022-02-01       Impact factor: 2.817

6.  Use of 18F-FDG-PET/CT for Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas.

Authors:  Dao-Ning Liu; Zhong-Wu Li; Hai-Yue Wang; Min Zhao; Wei Zhao; Chun-Yi Hao
Journal:  Contrast Media Mol Imaging       Date:  2018-07-02       Impact factor: 3.161

7.  Kidney sparing giant retroperitoneal liposarcoma: Case report and literature review.

Authors:  Masjensen Argadjendra; Rudi Napitupulu; Redemptus Yudadi; Sakti Hoetama; Heru Seno Wibowo
Journal:  Int J Surg Case Rep       Date:  2019-02-21

8.  Maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography/computed tomography improves outcome prediction in retroperitoneal liposarcoma.

Authors:  Jinsoo Rhu; Seung Hyup Hyun; Kyung-Han Lee; Sung Jun Jo; Kyo Won Lee; Jae Berm Park; Sung Joo Kim
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

9.  A Giant Retroperitoneal Liposarcoma Encasing the Entire Left Kidney and Adherent to Adjacent Structures: A Case Report.

Authors:  Sung Don Oh; Sung Jin Oh; Byoung Jo Suh; Jin Yong Shin; Cheol Kyu Oh; Jong Kwon Park; Yeon Mee Kim; Bo Mi Kim
Journal:  Case Rep Oncol       Date:  2016-06-27

10.  Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma.

Authors:  Michael J Nathenson; Constance M Barysauskas; Robert A Nathenson; William F Regine; Nader Hanna; Edward Sausville
Journal:  World J Surg Oncol       Date:  2018-10-11       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.